Skip to content
Biodatica
Start free

AstraZeneca

Duarte, California

OncologyPhase IIIListed · AZN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

NIH P30 · $0.3M · Developmental Funds

2mo agoGrant renewalMay 19, 2026Source filing (opens the source filing in a new tab)

Momentum

72no change

Momentum 72 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jul 19, 2018

    Non Small Cell Lung Cancer (Stage III) · ACTIVE_NOT_RECRUITING · sponsor: AstraZeneca · A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

    ClinicalTrials.gov · NCT03521154 (opens the source filing in a new tab)

  2. Grant

    P30 · $269k · non-dilutive

    Apr 7, 2009

    EMORY UNIVERSITY · PI RAMALINGAM, SURESH S · NCI · award ends Mar 31, 2028 · Developmental Funds

    NIH RePORTER · NIH RePORTER 11322687 (opens the source filing in a new tab)

  3. Grant

    P30 · $3.1M · non-dilutive

    Apr 7, 2009

    EMORY UNIVERSITY · PI RAMALINGAM, SURESH S · NCI · award ends Mar 31, 2028 · Winship Cancer Institute Cancer Center Support Grant

    NIH RePORTER · NIH RePORTER 11322658 (opens the source filing in a new tab)

  4. Grant

    P30 · $395k · non-dilutive

    Apr 7, 2009

    EMORY UNIVERSITY · PI RAMALINGAM, SURESH S · NCI · award ends Mar 31, 2028 · Leadership, Planning and Evaluation

    NIH RePORTER · NIH RePORTER 11322694 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources